

Special Issue

PET and SPECT Molecular Imaging in Drug Development

Message from the Guest Editor

Our forthcoming Special Issue of Pharmaceuticals, entitled “PET and SPECT Molecular Imaging in Drug Development”, will focus on the pivotal role of Positron Emission Tomography (PET) and SPECT (Single-photon emission computed tomography) in advancing drug development. Both, PET and SPECT imaging offer non-invasive insights into molecular processes, pharmacokinetics, and target engagement, enabling researchers to optimize drug candidates and predict clinical outcomes. We are seeking contributions on topics such as novel tracers, preclinical and clinical applications, safety and efficacy assessments, quantitative data analysis, personalized medicine, and regulatory perspectives. This Special Issue will serve as a platform for cutting-edge research, innovative methodologies, and case studies showcasing the impact of PET and SPECT imaging on drug development. We aim to create a bridge between academia and industry, fostering collaborations that translate PET- and SPECT-based discoveries into transformative therapies.

Guest Editor

Dr. Hyun Soo Park

Department of Molecular Medicine and Biopharmaceutical Sciences,
Graduate School of Convergence Science and Technology, Seoul
National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of
Korea

Deadline for manuscript submissions

closed (10 November 2024)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/189204

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)